Adcock Ingram appoints CEO

22 April 2014

kevin-wakeford-adcock-ingram-xxx-high-res-1

South African drugmaker Adcock Ingram (AIP: SP) has announced the appointment of Kevin Wakeford (pictured) as Chief Executive Officer, with immediate effect. Mr Wakeford succeeds Dr Jonathan Louw, who resigned as CEO of Adcock Ingram on 1 April, 2014.

Mr Wakeford joins Adcock Ingram following more than 10 years’ experience with the Bidvest Group Limited, where he served as Chief Executive Officer of Bidvest Travel and Aviation. Prior to joining Bidvest, Mr Wakeford spent nine years in the Southern Sun Hotel group and was Group Financial Manager at SA Breweries.

Mr Wakeford was educated at the University of Cape Town after which he served articles at Arthur Young.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK